Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Table 2 Efficacy data at baseline, Week 24, and change from baseline by MDA response, mean (SD)

	Baseline			Week 24		Change from BL
	MDA-R (n = 152)	MDA-NR (n = 322)	p	MDA-R (n = 152)	MDA-NR (n = 322)	MDA-R (n = 152)	MDA-NR (n = 322)	Diff.	p
SF-36 PCS	35.8 (9.4)	31.9 (8.9)	< 0.001	48.1 (7.1)	35.0 (9.6)	12.3 (9.0)	3.1 (7.8)	9.2 (8.2)	< 0.001
SF-36 MCS	49.3 (11.8)	46.8 (12.6)	0.047	53.7 (8.3)	50.5 (11.3)	4.4 (11.5)	3.8 (9.7)	0.7 (10.3)	0.51
EQ-5D-5 L HSI	0.62 (.20)	0.56 (.21)	0.003	0.82 (.14)	0.63 (0.17)	0.20 (0.20)	0.07 (0.20)	0.13 (0.20)	< 0.001
EQ-5D VAS	57.5 (21.0)	53.2 (20.3)	0.040	80.0 (16.6)	58.9 (20.3)	22.5 (21.7)	5.7 (22.4)	16.8 (22.2)	< 0.001
WPAI-SHP
% absenteeism	7.8 (20.4)^a	6.2 (18.0)^b	0.53	4.3 (15.1)^a	8.2 (22.7)^b	−3.5 (20.5)^a	2.0 (25.7)^b	−5.5 (23.9)	0.096
% presenteeism	33.8 (23.8)^c	40.9 (25.6)^d	0.061	6.8 (9.0)^c	27.7 (22.0)^d	−27.0 (23.3)^c	−13.2 (27.0)^d	−13.74 (25.67)	< 0.001
Overall work impairment	36.0 (25.7)^c	42.2 (26.5)^d	0.12	9.8 (13.4)^c	30.2 (23.8)^d	−26.2 (25.2)^c	−12.1 (28.0)^d	−14.1 (27.0)	< 0.001
% activity impairment non-work	42.2 (25.9)^e	52.7 (24.9)^f	<.001	10.0 (12.0)^e	37.9 (24.9)^f	−32.2 (26.9)^e	−14.9 (28.4)^f	−17.4 (27.9)	< 0.001

Number of patients with data available where different from total n:^an = 84; ^bn = 142; ^cn = 82; ^dn = 134; ^en = 152; ^fn = 321
Abbreviations BL = baseline, Diff. = difference, EQ-5D-5 L = European Quality of Life 5 Dimension 5 Level Health Questionnaire, HSI = Health State Index, MCS = mental component summary, MDA = minimal disease activity, PCS = physical component summary, MDA-R = MDA-responder, MDA-NR = MDA-non-responder, SF-36 = 36-Item Short Form Health Survey, VAS = visual analog scale, WPAI-SHP = Work Productivity and Activity Impairment–Specific Health Problem

ISSN: 2520-1026